Canada Markets closed

Alpha Cognition Inc. (ACOGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.8817+0.0217 (+2.52%)
At close: 03:20PM EST
Sign in to post a message.
  • H
    Harris
    Back into an uptrend despite the rough market condition over the past few days. And with $ACOG's leading drug candidate's, ALPHA-1062, results set to be released early next year, I'm expecting big things to come. Q3 results were as expected, with no surprise loss. Plus, the $5.6M in cash should continue to support the company well into next year.

    https://www.businesswire.com/news/home/20211130005165/en/Alpha-Cognition-Reports-Third-Quarter-of-Fiscal-2021-Results
  • p
    partystocker
    Alpha Cognition released some strong third-quarter numbers yesterday, stating they’ve completed Q3 with 5.6 million in cash and equivalents.

    Following this news, shares have strongly broken above a descending triangle that has been forming since mid-October!

    $ACOG.V is expecting to deliver top-line results of their ALPHA-1062 pivotal trial in Q2 2022. They’ll also be delivering top-line results for their TBI and Progranulin programs in Q1.

    This is exactly the kind of positive news I was looking for to catalyze shares into a break above the descending triangle formation. Looking for shares to take a good bullish run this week!

    Shares of $ACOG are currently trading at $1.15 and the company is valued at $70.72 million.

    https://ceo.ca/@businesswire/alpha-cognition-reports-third-quarter-of-fiscal-2021
  • T
    Troy
    I am optimistic that $ACOG's treatment could become widely available fast, especially considering how large the market is for Alzheimer's and ALS treatment is. Alzheimer's healthcare costs are around 355 billion per year, and about 30% of people discontinue treatment. $ACOG will reduce that number while also capitalizing on that portion of the dissatisfied market
  • p
    partystocker
    Alpha Cognition $ACOG/$ACOG.V is testing support at $1.12 today and I’m looking for a break above the current bearish trend as shares are up ~5% today. The RSI and Stochastic oscillator are currently at low points so I’m expecting an upward swing in prices.

    $ACOG.V is currently working on a gene therapy to treat ALS. The drug, ALPH-0602, is currently in preclinical development and has been patented and received Orphan Drug Designation from the FDA. I’m keeping alerts set for any developments as the right catalyst could send prices of $ACOG skyrocketing.

    $ACOG.V is currently trading at $1.11 and the company is valued at $67.03 million.

    https://www.alphacognition.com/our-approach/alpha-0602/
    Alpha Cognition Inc. brings excitement and passion to our work with the goal of positively impact the lives of people living with Alzheimer’s and ALS.
    Alpha Cognition Inc. brings excitement and passion to our work with the goal of positively impact the lives of people living with Alzheimer’s and ALS.
    www.alphacognition.com
  • S
    StockHawk
    ACOG has appointed Dr.Cedric O’Gorman (M.D.) as their Chief Medical Officer.

    O'Gorman will support $ACOG's clinical-stage ALPHA-1062 & ALPHA-0602 drugs by leading medical, clinical and regulatory functions and he will serve as a member of the executive management team.

    O’Gorman's past experience includes
    - Senior Vice President at Clinical Development and Medical Affairs at Axsome Therapeutics
    - Vice President of Medical Affairs at Intra-Cellular Therapies
    - U.S. Medical Lead for Psychiatry at Genentech/Roche.
    - Representing medical affairs on several branded neuroscience products for schizophrenia, bipolar disorder, and major depressive disorder at Pfizer

    Overall I think this is a really good new hire and will bode well for $ACOG

    More info here: https://finance.yahoo.com/news/alpha-cognition-appoints-cedric-o-140000680.html

    $ACOG @ $1.10/share

    MC $67.646M
  • H
    Henry
    Alpha Cognition has immense potential to capture major market share of ALZ treatment, a $355B market expected to grow to $1.1T by 2050. A-1062 taps into the gap where 8/10 #AD patients cease treatment due to side-effects. $ACOG.v is on track for rapid approval to market. The pivotal trial stages will begin Q3 '21 with top-line results expected before end of '21. https://www.alphacognition.com/our-approach/alpha-1062/
  • H
    Henry
    Don't miss this update with $ACOG CEO, providing an update on clinical programs. Consider these catalysts moving into '22 - top line data read out expected in Q1/2 '22, patient tolerability trials commence early '22, interim readout in latter '22, & plans to file NDA for its lead compound representing near product approval. https://www.youtube.com/watch?v=VHCjmN1dR9g&ab_channel=SNNNetwork
    Alpha Cognition Talks Update on Clinical Programs and Top Line Data Read Out in First Half of 2022
    www.youtube.com
  • p
    partystocker
    Shares of Alpha Cognition $ACOG/$ACOG.V are forming into a strong downward triangle pattern as their bearish trend slows. As price action continues to consolidate towards $1.12 I’m watching closely for a catalyst to lead to a break above the pattern.

    $ACOG.V closed out a $14.4 million public offering at the beginning of October so I’ll be expecting some announcements on what the company has been able to do with the funds. Hopefully we can get some positive news on their products in development.

    $ACOG is currently trading at $1.12 and the company is valued at $68.88 million.

    https://ceo.ca/@newsfile/alpha-cognition-announces-closing-of-144-million
    Vancouver, British Columbia--(Newsfile Corp. - October 1, 2021) - ALPHA COGNITION INC. (TSXV: ACOG) (OTCQB: ACOGF) ("Alpha" or the "Company"), is pleased to announce that it has closed its previously announced public offering of units (the "Units") f
    Vancouver, British Columbia--(Newsfile Corp. - October 1, 2021) - ALPHA COGNITION INC. (TSXV: ACOG) (OTCQB: ACOGF) ("Alpha" or the "Company"), is pleased to announce that it has closed its previously announced public offering of units (the "Units") f
    ceo.ca
  • p
    partystocker
    Shares of Alpha Cognition have really begun to see a decrease in volatility and consolidate into support at $1.12.

    I think we can expect to see a continued downward consolidation towards support for the short term. High insider shareholding as well as a low short ratio reinforce this prediction of price stabilization.

    Hopefully $ACOG.V can deliver some news and updates soon, as I haven’t heard much since their presentation at the LD Micro conference.

    $ACOG is currently trading at $1.14 and the company is valued at $70.11 million.
  • H
    Henry
    Alpha Cognition CEO Michael McFadden presented this morning at the Q4 Investors Summit Group. This was a highly informative session that presented significant lab studies, data and commercialization strategies for their Alpha-1062 treatment which is essentially set to revolutionize the Alzheimer's treatment industry.

    Tons of upside potential tapping into the $35B ALZ treatment market where 8/10 patients seek treatment and only 4.5/10 stay in treatments due to side-effects of current treatments, A-1062 is in trials and demonstrating strong improvement in side-effect profiles.

    You can view the recording on-demand, here: https://us06web.zoom.us/webinar/register/WN_5oxO1tQORQKs2TZDYxM-yw
  • N
    Nan
    good to see $ACOG.V in the green today, its been a while since we've received new updates from Alpha. neurodegenerative diseases are a continuing core area for new studies and trials to find better treatments and eventually, a cure. both treatments and a cure are the need of the hour and once established will stay for the long run which is why I have so much faith in $ACOG.V, their treatments are long-term performers and I really think the price will show a sharp incline the moment we receive new updates from the company.

    td, $ACOG.V trading at $1.16 with market cap at $71.34 M
  • S
    StockHawk
    If you're interested in the biopharma sector I would highly recommend checking out Alpha Cognition Inc. ( $ACOG.V ACOGF ).

    $ACOG is a biopharmaceutical company that is in clinical stages for developing treatments for under-served neurodegenerative diseases, like Alzheimer's Disease and ALS.

    In a recent interview $ACOG's CEO, Michael McFadden, described the company's two drugs, ALPHA-1062 and ALPHA-602.

    He said that Alpha-1062 is a pro-drug of a drug that was developed by J&J and approved in the mid-2000's. J&J's version of the drug had several harsh side effects, however $ACOG's version is optimized to minimize side effects.

    He describes Alpha-602 as a "pro granulin gene therapy. That is a full link pro granulin, pro granulin is a protein chain and that drug has shown applicability for a number of disease states." Additionally, McFadden says that Alpha-602 could possibly become a curative option for ALS.

    On financing, McFadden says that the $14.4M that the company gained from their Canadian IPO will be used for commercialization of their drugs.

    If you think that $ACOG and the drugs they are developing seem promising, I would highly recommend looking into them and this interview is a great place to start:

    https://stockhouse.com/opinion/interviews/2021/10/25/bringing-hope-to-people-living-with-neurodegenerative-diseases?utm_source=twitter&utm_medium=stockhouse&utm_term=92163597-a8bd-45bf-876e-75e8710c4199&utm_content=&utm_campaign=

    Currently $ACOG is trading at $1.29 (down 3% today), with a $79.33M market cap.
    Alpha Cognition Inc. (TSX-V.ACOG, OTCMKTS: ACOGF, Forum) is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases. Stockhouse Media’s Dave Jackson caught up recently with Company CE
    Alpha Cognition Inc. (TSX-V.ACOG, OTCMKTS: ACOGF, Forum) is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases. Stockhouse Media’s Dave Jackson caught up recently with Company CE
    stockhouse.com
  • N
    Nan
    great video of $ACOG.V CEO talking about possible treatments in development for treating the symptoms of Alzheimer’s https://www.youtube.com/watch?v=4S4g1dVckN8
    he also added that results from its lead drug ALPHA-1062 are targeted for release in Q1 of 2022

    td, $ACOG.V trading at $0.75 with market cap at $34.06 M
    Alpha Cognition to begin its pivotal clinical trial to treat symptoms of Alzheimer’s disease
    www.youtube.com
  • S
    StockHawk
    Alpha Cognition Inc. ( $ACOG.V ACOGF ) is developing medicines for the treatment of ALS, Alzheimer's and other under-served neurodegenerative diseases.

    One of the drugs they are developing, Alpha-1062 helps with the cognitive effects of Alzheimer's.

    A-1062 is very similar to a drug that was approved in the mid-2000s (developed by J&J) but has serious side effects that are hard for most to bear. $ACOG is developing their version of the drug because adherence to J & J version was low and therefore was consisting helping with long-term outcomes.

    It has been found that if patients do adhere to drugs like A-1062, 80% of Alzheimer's patients that are galantamine-treated live independently versus 30% of untreated patients at 36 months (https://fb.watch/9mwQPOULdq/)

    Additionally, $ACOG is developing Alpha-602 which is a progranulin gene therapy drug.

    A-602 could possibly become a curative option for ALS disease.

    $ACOG is currently trading at $1.17, MC is ~$72M
  • W
    Waves
    Alpha Cognition Inc. ($ACOG $ACOG.v $ACOGF) will be presenting at the Q4 Virtual Summit hosted by the Investors Summit Group.

    $ACOG is scheduled to present at 10:15 AM ET on November 17th, 2021.

    This is a great opportunity to learn about $ACOG and get updated on their recent developments.

    Sign up for the event here:
    https://us06web.zoom.us/webinar/register/WN_5oxO1tQORQKs2TZDYxM-yw

    You can find out more about $ACOG and the event here:
    https://www.meetmax.com/sched/event_74761/__preslist_cp.html
    Welcome! You are invited to join a webinar: Q4 Virtual Summit: Alpha Cognition. After registering, you will receive a confirmation email about joining the webinar.
    Welcome! You are invited to join a webinar: Q4 Virtual Summit: Alpha Cognition. After registering, you will receive a confirmation email about joining the webinar.
    us06web.zoom.us
  • S
    StockHawk
    Interested in investing in a company that is developing ALS and Alzheimer's treatments?

    Alpha Cognition Inc. ( $ACOG.V ACOGF ) is in the clinical stages of developing medicines for the treatment of Alzheimer's Disease, ALS, and other under-served neurodegenerative diseases.

    One of the drugs they are developing, Alpha-1062, helps with the cognitive effects of Alzheimer's.

    A-1062 is very similar to a drug that was approved in the mid-2000s (developed by J&J) but has serious side-effects that are hard for most to bear.

    $ACOG's version of the drugs is optimized to minimize these side effects.

    $ACOG is also developing Alpha-602 which is a pro granulin gene therapy drug.

    A-602 has been shown to help with a number of ALS disease states and could possibly become a curative option for the disease.

    $ACOG has $14.4M from their Canadian IPO to use for the commercialization of their drugs.

    $ACOG is currently trading at $1.15 (up 2.7%), MC is $70.7M

    More info on $ACOG and their drugs here: https://www.alphacognition.com/
    Alpha Cognition Inc. brings excitement and passion to our work with the goal of positively impact the lives of people living with Alzheimer’s and ALS.
    Alpha Cognition Inc. brings excitement and passion to our work with the goal of positively impact the lives of people living with Alzheimer’s and ALS.
    www.alphacognition.com
  • p
    partystocker
    Things are still pretty quiet on the $ACOG front today- no news. That’s not to say there isnt a lot going on:

    $ACOG.V just presented at the LD Micro Main Event last week, and I think this will generate some serious investor interest.

    Plus, their ALPHA-1062 drug is still being worked on and looks insanely promising rn.

    All these lead me to believe $ACOG’s stock will get bumped up out of its current trend very soon.

    Price down a tiny bit at $1.16. Current value is at $71.34M.
  • N
    Nan
    I've been following $ACOG.V for a while now and I have to mention, their approach towards finding better treatments for neurodegenerative diseases, specially the ones under served like Alzheimer’s has always fascinated me. I think they are doing a fab job, and I am really invested in seeing what they deliver next!

    td, $ACOG.V trading at $1.12 with market cap at $68.88 M
  • p
    partystocker
    Alpha Cognition Inc. $ACOG/$ACOG.V shares are recovering nicely from a small dip earlier this month.

    $ACOG’s Alzheimer's drugs are getting some serious attention from analysts. In a recent statement, Chelsea Stellick of iA Capital Markets initiated a speculative buy rating for $ACOG with a price target of $5.00 per share. At current prices of $1.19 this equates to a 420% price increase.

    $ACOG’s ALPHA-1062 Alzheimer's treatment is currently in a de-risked trial with strong data behind it. These trials also only require bioequivalence rather than efficacy. This article gives a great rundown of $ACOG’s current pharmaceutical lineup as well as some breakdown on revenue projections for their new products.

    With prices trading at near recent lows, this could be a great time to scoop up some shares of $ACOG.

    $ACOG is currently trading at $1.19 and is valued at $73.18M.

    https://www.cantechletter.com/2021/10/alpha-cognition-could-have-a-best-in-class-alzheimers-drug-ia-capital-says/#
    Chelsea Stellick of iA Capital Markets likes what she sees in Alpha Cognition, initiating coverage with a “Speculative Buy” rating and target price of $5.00/share for a projected return of 265 per cent in an update to clients on October 19.
    Chelsea Stellick of iA Capital Markets likes what she sees in Alpha Cognition, initiating coverage with a “Speculative Buy” rating and target price of $5.00/share for a projected return of 265 per cent in an update to clients on October 19.
    www.cantechletter.com
  • S
    StockHawk
    I'm always happy to put my money in a company that is going to do good in the world as well as do good on the market. Alpha Cognition Inc's two main drugs they are developing are ALPHA-1062 and ALPHA-602:

    Alpha-1062 is very similar to a drug that was developed by J&J and approved in the mid-2000s but $ACOG's version is optimized to minimize side effects.

    Alpha-602 is a progranulin gene therapy drug that has been shown to help with a number of disease states and could possibly become a curative option for ALS.

    From a financial POV $ACOG is looking solid, having gained $14.4M from their Canadian IPO (which they intend to use for commercialization of ALPHA-1062 and ALPHA-602)